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The timely reconstitution and regain of function of a donor-derived immune system is of 
utmost importance for the recovery and long-term survival of patients after allogeneic 
hematopoietic stem cell transplantation (HSCT). Of note, new developments such as 
umbilical cord blood or haploidentical grafts were associated with prolonged immu-
nodeficiency due to delayed immune reconstitution, raising the need for better under-
standing and enhancing the process of immune reconstitution and finding strategies to 
further optimize these transplant procedures. Immune reconstitution post-HSCT occurs 
in several phases, innate immunity being the first to regain function. The slow T cell 
reconstitution is regarded as primarily responsible for deleterious infections with latent 
viruses or fungi, occurrence of graft-versus-host disease, and relapse. Here we aim to 
summarize the major steps of the adaptive immune reconstitution and will discuss the 
importance of immune balance in patients after HSCT.
Keywords: hematopoietic stem cell transplantation, immune reconstitution, infection, graft-versus-leukemia 
effect, graft-versus-host disease
iNTRODUCTiON
The reconstitution of different immune cell subsets after allogeneic hematopoietic stem cell 
transplantation (HSCT) (Figure 1) occurs at different time points summarized in Table 1. After 
conditioning therapy, patients undergo an “aplastic phase” (severe neutropenia or pre-engraftment 
phase) until neutrophils recover. The total nucleated cell (TNC) dose and CD34+ cell dose within 
the graft source are important factors contributing to the rate of engraftment and outcome after 
HSCT. Umbilical cord blood (UCB) grafts contain lower TNC levels compared to bone marrow 
transplant (BMT) and peripheral blood stem cell transplant (PBSCT), what increase the time of 
neutrophil engraftment from ~14 days after PBSCT and 21 days after BMT to 30 days after UCB 
transplantation (1, 2). Moreover, recent study showed that high TNC cell dose was associated with 
improved overall survival (OS), decreased relapse, and increased incidence of chronic graft- versus-
host disease (GvHD) in patients receiving PBSCT (3). On the other hand, it has been presented that 
patients with higher CD34+ dose within PBSCT had faster platelet engraftment, but lower OS and 
increased relapse (4).
TABLe 1 | immune reconstitution after allogeneic HSCT.
immune cells Duration after allogeneic HSCT
Neutrophils >0.5 × 109/L ~14 days for PBSC, ~21 days for BM, and 
~30 days for CB
NK cells 30–100 days
T cells 100 days
CD19+ B cells 1–2 years
PBSC, peripheral blood stems cells; BM, bone marrow; CB, cord blood; NK cells, 
natural killer cells.
FiGURe 1 | Overview of immune cell differentiation. The figure shows the different types of immune cells and their development from different precursors. The 
reconstitution of innate immunity occurs rapidly within 20–30 days after allogeneic HSCT while reconstitution of adaptive immunity is delayed following HSCT and 
can require up to 1 year. Natural killer (NK) cells, monocytes, granulocytes, and dendritic cells are derived from myelomonocytic progenitor cells. B and T cells 
differentiate from lymphoid progenitor cells and require specialized microenvironments in order to efficiently differentiate from primitive progenitors, and typically show 
delayed and incomplete recovery. Reprinted by permission from Macmillan Publishers Ltd.: Bone Marrow Transplantation (5), copyright (2005).
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The infections encountered during the pre-engraftment phase 
consist primarily of bacterial and fungal infections that are rea-
sonably well controlled by medications given for prophylaxis and 
treatment (6) (Figure 2). The first 100 days after HSCT (engraft-
ment phase) are characterized by cellular immunodeficiencies 
due to a reduced number of natural killer (NK) cells of the innate 
immune system and T cells of the adaptive immune system. 
This renders patients especially susceptible to viral reactivations 
including cytomegalovirus (CMV) and Epstein–Barr virus (EBV) 
as well as viral diseases (7, 8).
The recovery of the T cell compartment relies on peripheral 
expansion of memory T cells, driven by cytokines as well as 
allogeneic antigens encountered in the host, and is followed by 
the production of naive T cells in the thymus (5). CD4+ T cells 
reconstitute later than CD8+ T cells and depend more on thymic 
generation of CD4+CD45RA+ naive T cells after HSCT explain-
ing the reported inversion of the CD4/CD8 ratio (9). About 
3  months after HSCT, CD4+ T cell numbers of about 200/μL 
have been observed (10). T cell receptor (TCR) rearrange-
ment excision DNA circles (TRECs) have been investigated as 
surrogate parameters for reconstitution of thymus-derived 
CD4+CD45RA+ naive T cells (11). TREC levels remain low until 
3–6  months after allogeneic HSCT (5). A special subgroup of 
CD4+ cells are regulatory T cells (Tregs), which may be important 
for a better outcome after allogenic HSCT (12). Tregs suppress 
the activity of effector T cells, thus reducing inflammation and 
promoting immune homeostasis after allogenic HSCT (13). 
Clinical, preclinical, and experimental models have shown that 
Treg reconstitution plays a critical role in amelioration of GvHD 
while preserving the graft-versus-leukemia (GvL) effect (14, 
15). Increasing age is associated with thymic atrophy and loss of 
function (16). Cycling of mature lymphocytes maintains num-
bers of mature T cells by homeostatic peripheral expansion (5). 
Naive CD4+ and CD8+ T cells rely on interleukin-7 (IL-7) and 
TCR engagement for survival and expansion (17). CD8+CD27+ 
FiGURe 2 | Time line of complications after allogeneic HSCT. The figure shows the most prevalent complications after HSCT according to the three phases of 
engraftment. Concomitant infectious complications consisting of bacterial, fungal, and viral infections are shown according to their occurrence as well as association 
with acute and chronic GvHD during different phases of follow-up: (1) pre-engraftment, (2) engraftment, and (3) post-engraftment phase. Abbreviations: CMV, 
cytomegalovirus; aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease.
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memory T cells can be maintained and expanded by cytokine 
signals alone involving IL-7 and interleukin-15 (IL-15) (18). In 
older patients, the lack of CD4+CD45RA+ naive T cells with a 
broad TCR repertoire leads to an increased risk for opportunistic 
infections and probably also to increased risk of leukemic relapse 
(19, 20). The lack of CD4+CD45RA+ naive T cells is additionally 
aggravated by GvHD (21, 22).
The B cell compartment representing the humoral immunity 
is the slowest to reconstitute and may take up to 5  years after 
allogeneic HSCT. Transitional CD19+CD21lowCD38high B cells are 
the first B cells emigrating from the bone marrow (BM) and are 
elevated in the peripheral blood (PB) in the first months after 
HSCT before their percentage progressively decreases, while the 
proportion of more mature B cell subpopulations increases (23). 
The lack of CD19+CD27+ memory B cells, decreased levels of 
circulating immunoglobulins, impaired immunoglobulin class 
switching, and a loss of complexity in immunoglobulin gene 
rearrangement patterns leave allogeneic HSCT patients vulner-
able to encapsulated bacteria such as Streptococcus pneumoniae 
and Haemophilus influenzae (1, 24). In this review, we summarize 
the reconstitution of the adaptive immunity and discuss the 
importance of achieving immune balance after HSCT.
ADAPTive iMMUNiTY
immune Reconstitution of B Cells after 
Allogeneic Hematopoietic Stem Cell 
Transplantation
Patients undergoing HSCT often experience late recovery of 
B cell numbers leading to a defect of B cell mediated immunity. 
Generally, B cell numbers recover to normal counts within 
12  months after HSCT (25), although complete recovery may 
take up to 2 years. In the first few months, very few circulating 
B cells have been observed (25, 26) and within 1–2 years follow-
ing HSCT, B cell numbers reach levels exceeding normal adult 
individual ones followed by gradual decline, similarly to the 
normal ontogeny in young children (26). First B cells emerging 
into the periphery are CD19+CD21lowCD38high transitional 
B cells, which subsequently decrease in percentages while mature 
CD19+CD21highCD27− naive B cells are being replenished (1, 23). 
Transitional B cells were first described as CD24highCD38high (23). 
Later on, another marker of transitional B cells was identified, 
distinguishing between T1 and T2 transitional cells. T1 cells 
were reported as CD21low and described as the first B cell popula-
tion emigrating from the BM, which subsequently differentiate 
toward CD21+, T2 phenotype and serve as precursors of the 
CD19+CD21highCD27− naive B cell pool in PB and tissues (27). 
Complete reconstitution of the B cell compartment includes the 
recovery of both CD19+CD21highCD27− naive and CD19+CD27+ 
memory B cells. Reconstitution of memory B cells occurs upon 
environmental or vaccine-based antigen exposure and requires 
CD4+ T cell help (28). Complete CD19+CD27+ memory B cell 
development may take up to 5 years after HSCT (26). In the study 
by Corre and colleagues, numbers of CD19+CD21highCD27− naive 
B cells normalized by 6 months and reached above normal values 
around 24 months after myeloablative conditioning for allogeneic 
HSCT (29). CD19+CD27+ memory B cells remained persistently 
low during the 2 years of follow-up (29). Other authors similarly 
reported relatively fast naive B cell reconstitution followed 
by delayed memory B cell recovery (30, 31). In addition, early 
expansion of CD19+CD5+ B cells has been reported (29, 32), a 
subset described as pre-naive circulating B cells representing a 
distinct intermediate phenotype between transitional and naive 
B cells (33). These cells showed only partial responses to B cell 
receptor (BCR) stimulation and CD40 ligation, but similarly 
to CD19+CD21highCD27− naive B cells, these were capable to 
differentiate into plasma cells and had the ability to function as 
antigen-presenting cells (APCs) (33).
In the first 2 years following allogeneic HSCT, B cell function 
remains compromised. Different B cell subpopulations often 
reconstitute over a different period of time contributing to a 
defective humoral response. Delayed T cell recovery and the 
reversed CD4/CD8 ratio may also contribute to low circulating 
B cell numbers following HSCT (26). Furthermore, CD19+CD27+ 
memory B cells can be influenced by low T helper cells as they 
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require their help for isotype switching (26). In addition, somatic 
hypermutation seems to be diminished even in the presence of 
normal donor CD4+ T cell numbers, implying an environmental 
defect (26, 34). Normal levels of serum IgM are usually measur-
able 3–6  months after HSCT (35, 36), followed by normaliza-
tion of serum IgG1/IgG3, IgG2/IgG4, and IgA similar to that 
observed during normal development in the first years of life (37). 
However, in some patients, long-term antibody class deficiencies 
have been reported (38). The immunoglobuline heavy chain 
(IgH) repertoire is often characterized by delayed class switch-
ing and oligoclonal dominance with specific rearrangements 
dominating at different time points in these patients (36, 39). 
Measurement of B lymphocyte repertoire diversity by analysis 
of IgH complementarity determining region 3 (CDR3) revealed 
limited variation of IgH CDR3 repertoire in CD19+CD27+ 
memory B lymphocytes compared to CD19+CD21highCD27− 
naive B cells at 3 and 6 months after allogeneic HSCT. Decrease 
in CD19+CD27+ memory B cell IgH CDR3 repertoire, but not 
CD19+CD21highCD27− naive B cell one, was also observed when 
compared to healthy controls suggesting a role of CD19+CD27+ 
memory B cells in oligoclonal restriction (35). Both CD19+CD27+ 
memory B cells and CD19+CD21highCD27− naive B cells reach 
normal diversity, comparable to healthy individuals, 12 months 
after HSCT (35).
Different settings of HSCT may also influence B cell recovery. 
Patients receiving antithymocyte globulin-fresenius (ATG-F) 
presented delayed CD19+ B cell recovery up to 5 months after 
HSCT compared to non-ATG-F patients (40). ATG is a potent 
immunosuppressant administrated before HSCT to prevent 
graft rejection and to reduce incidence of acute and chronic 
GvHD in patients receiving grafts from unrelated donors (40, 
41). Absolute CD19+ B cells normalized 1 year after HSCT in 
both groups. ATG-treated patients had significantly worse 
CD19+CD21highCD27− naive B cell and CD19+CD27+ memory 
B cell regeneration within the first month after HSCT indicating 
a negative impact of ATG on B cell immune reconstitution (40). 
Depending on the brand, ATG may also have immunomodu-
latory effects on B cells (42). Slow B cell recovery has been 
observed in patients receiving non-myeloablative conditioning 
compared to those given myeloablative therapy, with reduced 
B cell numbers observed in most patients up to 12 months after 
non-myeloablative therapy for HSCT (43). However, these find-
ings may in part be explained by older patient age and higher 
incidence of acute GvHD in this patient cohort (43). Both acute 
and chronic GvHD have been associated with delayed B cell 
reconstitution, and reduction or lack of B cell precursors in the 
BM has been observed in these patients compared to patients 
without GvHD (44). In a study on 93 allograft recipients, the 
number of BM B cell precursors on day 30 after HSCT was signifi-
cantly lower in patients later developing grades 2–4 acute GvHD 
compared to patients with grades 0–1 disease (44). Moreover, 
patients developing extensive chronic GvHD within 1 year after 
transplantation had lower percentages of B cell precursors on 
day 365 compared with patients without chronic GvHD or with 
limited chronic GvHD (44). However, the effect of acute and 
chronic GvHD could not be separated from the possible influ-
ence of glucocorticoid treatment in this study due to low patient 
numbers suggesting B cell deficiency after transplantation may 
in part be a result of inhibition of B  lymphopoiesis by GvHD 
and/or its treatment (44). In addition, a decrease of absolute 
CD19+ B cells in patients at first diagnosis of chronic GvHD 
and a disturbance of B cell homeostasis in patients with active 
chronic GvHD have been observed (45,  46). Stem cell source 
may also influence numbers of circulating B cells with higher 
counts detected in recipients of peripheral blood stem cells 
(PBSC); however, this observation may be attributed to the 
higher amount of mature B cells in PBSC grafts compared with 
BM (44, 47, 48).
Even patients who show recovery of overall CD19+ B cell num-
bers are not considered fully immunocompetent and as a result 
of decreased B cell function, impaired vaccine responses to infec-
tious antigens have been observed (26). Lack of CD19+CD27+ 
memory B cells, decrease of circulating immunoglobulins, and 
impaired immunoglobulin gene rearrangement render these 
patients susceptible to encapsulated bacteria and viruses (1, 24).
immune Reconstitution of T Cells and 
Their Role after HSCT
CD4+ and CD8+ T cells reconstitute within the first year after 
HSCT and enable defense against viral or fungal infections, as 
well as maintaining the GvL effect. A subset of CD4+ T cells are 
so called regulatory T cells (Tregs). In the next paragraph, we aim 
to summarize their development and function in patients after 
allogeneic HSCT.
Regulatory T Cells in immune 
Reconstitution and Their impact after 
HSCT
Regulatory T Cells
Tregs are a subset of CD4+ T cells whose function is to sup-
press immune responses and maintain self-tolerance (49). 
A transcription factor called FoxP3, a member of the fork head 
family of transcription factors, is critical for the development 
and function of Tregs and is used as a definite marker to identify 
Tregs (49, 50). Tregs are a functionally mature subpopulation 
of T cells and can also be induced from CD4+CD45RA+ naive 
T cells in the periphery (51). Natural Tregs (nTregs) are derived 
from the thymus and are characterized by the co-expression 
of CD4, high expression of CD25 and FoxP3 (52). Induced or 
adaptive Tregs (iTregs) are generated in peripheral lymphoid 
organs in the presence of transforming growth factor beta 
(TGF-β) (53) (Figure 3).
Some recent studies have shown that nTregs are more stable 
than iTregs in relation to their differential DNA methylation 
profiles and other epigenetic regulations of FoxP3 (54, 55).
Tregs in Immune Balance
Tregs can downregulate immune responses by (a) production 
of inhibitory cytokines and (b) a contact-mediated effect on 
APCs. Tregs produce the anti-inflammatory cytokine inter-
leukin-10 (IL-10) that inhibits production of interleukin-12 
(IL-12) by activated dendritic cells (DCs) and macrophages 
(56, 57). IL-10 also inhibits the expression of co-stimulators and 
FiGURe 3 | Development of natural and induced regulatory T cells. Natural regulatory T cells (nTregs) are derived from the thymus and are characterized by 
the co-expression of CD4, high expression of CD25 and FoxP3, and are collectively represented as CD4+CD25+FoxP3+ Tregs. Induced or adaptive regulatory T cells 
(iTregs) are generated in the peripheral lymphoid organs in the presence of transforming growth factor beta (TGF-β) and interleukin-2 (IL-2).
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major histocompatibility complex (MHC) class II molecules on 
DCs and macrophages and thus inducing tolerance within the 
immune system (56–58). Another anti-inflammatory cytokine 
produced by Tregs, TGF-β, inhibits the proliferation and effec-
tor functions of T cells and the activation of macrophages (59, 
60). TGF-β also regulates the differentiation of functionally 
distinct subsets of T cells, stimulates production of immuno-
globulin A (IgA) antibodies, promotes tissue repair after local 
immune and inflammatory reactions subside, and confers 
Treg-mediated immune reconstitution (56–58, 61). Tregs play 
a major role in regulation of epithelial inflammation and are 
strongly influenced by the interaction with the epithelial micro-
bial environment (62, 63).
Tregs in Animal Models of Hematopoietic 
Stem Cell and Solid Organ Transplantation
Tregs play an indispensable role in both solid organ transplant 
tolerance and in allograft tolerance after HSCT. In rodents and 
humans, a subpopulation of thymus-derived naive CD4+ T cells 
that co-express the IL-2R alpha chain, CD25, have potent sup-
pressive activity (64). Tregs mediate transplantation tolerance 
in experimental models of skin and/or solid organ transplanta-
tion (65) as well as tolerance to BM allografts (66). By allogeneic 
HSCT, malignant and non-malignant hematological disorders 
can be cured, but at the same time, treatment efficacy is lim-
ited due to occurrence of GvHD (67). Regulatory T cells have 
received considerable attention in recent years due to their 
ability to suppress the proliferation of conventional T  cells 
when added to donor grafts and prevention of GvHD in animal 
models (68). Using a mouse model, Edinger and colleagues 
have shown that CD4+CD25+ Tregs suppress GvHD after BMT 
without abrogating the GvL or graft-versus-tumor (GvT) effect 
(14) supporting the importance of Tregs in allogenic HSCT. 
Furthermore, Nguyen and colleagues demonstrated that the 
adoptive transfer of Tregs preserved thymic and lymphoid 
architecture of the host and hence accelerated posttransplant 
T cell immune reconstitution in a murine GvHD model (69).
Taylor and colleagues demonstrated that in vivo depletion 
of CD25+ T cells and depletion of CD25+ T cells in the trans-
plant inoculum, worsened GvHD whereas adoptive transfer of 
CD4+ CD25+ nTregs together with the BM graft ameliorated 
GvHD (70).
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While an increasing number of publications have focused 
on the biology of CD4+CD25+Foxp3+CD45ROlo naive Tregs in 
GvHD, less attention has been given to iTregs, probably due to 
the lack of proven cell surface marker that differentiate nTregs 
from iTregs. Fantini and colleagues demonstrated that iTregs can 
be generated from CD4+ T cells in the presence of TGF-β and 
can be expanded in culture (71). On the other hand, Koenecke 
and colleagues showed that administration of in vitro generated 
iTregs along with BM grafts containing alloreactive donor T cells 
did not provide any significant protection from lethal GvHD, 
due to limited in  vivo survival of these cells (72). They also 
demonstrated that iTregs lost their Foxp3 expression, along with 
a loss of suppressive function early after transplantation, thus 
making iTregs unsuitable for use in a therapeutic approach (72) 
if administered as an external cellular product. Not only iTregs 
but also nTregs have been shown to loose Foxp3 expression in 
a STAT3-dependent manner and can revert to a proinflamma-
tory phenotype under inflammatory conditions (73). Therefore, 
inflammation seems to affect Foxp3 expression in both natural 
and induced Tregs.
Although Tregs have long been assumed to be solely a subset of 
the CD4+ T cell compartment, a CD8+ Treg population has been 
recently described and shown to be capable of suppressing T cell 
responses (74). In terms of GvHD, Robb and colleagues reported 
that CD8+Foxp3+ Tregs suppressed GvHD and attenuated 
GvHD mortality after BMT in a mouse model (75). Interestingly, 
CD8+Foxp3+ cells were more suppressive than CD4+Foxp3+ cells 
(75). Using a rat model, Xystrakis and colleagues provided a first 
report on CD8+ Tregs conferring their regulatory properties via 
a cell to cell contact dependent mechanism to prevent GvHD 
and thus confirming CD8+Foxp3+ Tregs in a second species (76). 
Clinical studies on CD8+ Tregs at a functional level are scarce to 
date. However, Zheng and colleagues reported that human CD8+ 
Tregs potentially inhibit GvHD without compromising general 
immunity and GvL activity in humanized mouse models (77). 
Taken together, these findings provide an insight into the efficacy 
of both CD4+ and CD8+ Tregs as potential novel therapeutic 
approaches in clinic.
Tregs in Clinical Hematopoietic  
Stem Cell Transplantation
Many researchers have focused on evaluating Treg cell numbers 
after HSCT, since they play an important role in the amelioration 
of GvHD. Using PB of patients after transplantation, Li and col-
leagues demonstrated that the frequency of CD4+CD25+ Tregs 
was significantly downregulated in patients with severe acute or 
chronic GvHD (78). They also showed that a decreased level of 
CD4+CD25+ Tregs correlated with increased severity of GvHD 
(78). While the majority of studies focused on blood derived 
Tregs, there is little information on Tregs isolated from intesti-
nal tissues due to the lack of availability of repeated gut biopsies. 
Using immunoenzymatic labeling, Rieger and colleagues were 
the first to demonstrate that infiltrating Tregs decreased the 
signs of acute and chronic GvHD in intestinal mucosa (79). 
They showed that patients with acute and chronic GvHD had 
a complete lack of counter regulation indicated by a Foxp3+/
CD8+ T cell ratio identical to that of healthy individuals, while 
this ratio was increased in patients without GvHD (79). These 
results have been discussed controversially in the literature 
since Lord and colleagues demonstrated that Foxp3+ T cells 
were not decreased in PB or gastrointestinal tissues and that the 
frequency of Tregs did not correspond to disease incidence or 
severity (80). On the contrary, these investigators reported that 
Foxp3+ T cells were significantly upregulated in GvHD-afflicted 
intestinal mucosa when compared to non-GvHD mucosal tissues 
(80). This finding was further supported by Ratajczak and col-
leagues who observed an increased proportion of CD4+Foxp3+ 
T cells in patients with grades 2–4 compared to grades 0–1 acute 
GvHD (81). One possible explanation for these conflicting 
results may be the difficulty to discriminate natural and induced 
Tregs. It is possible that nTregs are decreased in GvHD while 
iTregs may be increased in order to compensate for the exag-
gerated inflammation during GvHD. Imanguli and colleagues 
observed an upregulation of functional markers such as CD3+, 
CD4+, CD27+, ICOS+, and CD39+ in Tregs that traffic into tissue 
including skin and oral mucosa exerting a suppressive func-
tion in patients with chronic GvHD (82). Interestingly, normal 
numbers of activated CD45−Foxp3hi Tregs were observed in 
tissue and PB of patients with chronic GvHD whereas naive or 
resting CD45RA+Foxp3+ Tregs that presumably control chronic 
GvHD effector cells were reduced compared to patients without 
chronic GvHD.
Tregs in GvHD: First-in-Man Clinical Trial
Studies in mouse models of GvHD have provided informa-
tion on the suppressive nature of Tregs and their potential to 
suppress and ameliorate GvHD without impairing the GvL 
effect. The first clinical trial using Tregs to suppress acute/
chronic GvHD in patients were completed recently. This 
“first-in-man-study” reported the adoptive transfer of ex vivo 
expanded CD4+CD25+CD127− Tregs in one patient with 
chronic GvHD and another with acute GvHD after HSCT with 
an HLA-identical sibling donor (83). Transfer of Tregs resulted 
in a reduction of the steroid dose administered, increased 
levels of circulating Tregs, and a decrease in inflammatory 
cytokine levels in the PB (83). Another “first-in-man-study” 
was reported after double UCBT in 23 patients, who received 
in vitro expanded 0.1–30 × 105 UCB CD4+CD25+CD127− Tregs 
per kilogram derived from partially HLA-matched third-party 
UCB units (15). There was a significant reduction in the inci-
dence of acute GvHD grades II–IV (43 versus 61%, P = 0.05) 
when compared to 108 historical controls without transfusion 
of Tregs. No toxicities, infections, relapse, or early mortality 
were observed suggesting that UCB Tregs could be beneficial 
for preventing acute GvHD (15). Furthermore, Di Ianni and 
colleagues reported a clinical trial in 28 patients receiving 
adoptively transferred CD4+CD25+CD127− Tregs after T-cell-
depleted haploidentical HSCT without further immunosup-
pression (13). Only 2 out of 28 patients developed grades II–IV 
acute GvHD and no chronic GvHD was observed. They showed 
that adoptive transfer of freshly isolated donor-derived Tregs 
4 days before inoculating the CD34+ stem cells prevented acute 
and chronic GvHD in the absence of further immunosuppres-
sion. Tregs promoted lymphoid reconstitution, improvement of 
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immunity to opportunistic pathogens (no CMV-related death 
of patients) without abrogating the GvL effect (13). In  addi-
tion, Hoffmann reported in vitro expansion of highly purified 
polyclonal human CD4+CD25high Tregs through the use of 
artificial APCs for repeated stimulation via CD3 and CD28 
in the presence of high-dose IL-2 (84). These cells not only 
maintained their phenotype and expressed suppressive activity 
but also maintained the expression of the lymph node homing 
receptors l-selectin and CCR7 (84). Furthermore, the same 
group reported results of a small phase I safety and feasibility 
trial where freshly isolated donor-derived CD4+CD25high Tregs 
were infused into nine patients with high risk for leukemic 
relapse after cessation of systemic GvHD prophylaxis (12). 
After 8  weeks, additional CD4+ T cells were administered to 
promote GvL activity. Patients showed no signs of GvHD nor 
opportunistic infections or early disease relapse supporting the 
safety and efficacy of Treg transfusion (12). This has led to a 
phase II clinical trial for the treatment of patients with steroid-
refractory acute GvHD using freshly isolated CD4+CD25high 
Tregs that is currently ongoing. Taken together, these early tri-
als suggest that Tregs could be a novel approach for prophylaxis 
and treatment of patients with acute GvHD in larger clinical 
trials. The impact of Treg transfusion on the immune reconsti-
tution has to be further investigated.
induction of Regulatory T Cells after HSCT
Tregs induce tolerance and maintain immune homeostasis (51). 
A major challenge of Treg cell therapy is their relative scarcity in 
PB (0.5–1% of CD4+CD25high T cells) (85). In 2011, Hippen and 
colleagues presented two individual reports regarding the genera-
tion of induced Tregs on a large scale (86) and ex vivo expansion 
of natural Tregs (86). Both methods focus on the development 
of expansion protocols for either type of Tregs to obtain higher 
yields for clinical trials on treatment or prevention of GvHD 
(86). In patients with chronic GvHD, Matsuoka and co-workers 
reported that daily administration of low-dose IL-2 induced 
selective expansion of functional CD4+CD25+CD127− Tregs, 
improved chronic GvHD, restored CD4+ T cell homeostasis, and 
promoted the reestablishment of immune tolerance (87). Koreth 
et  al. reported the case of 29 chronic GvHD patients that the 
administration of subcutaneous low dose IL-2 rapidly induced 
preferential and sustained Tregs expansion without any immune 
impairment (88). This suggests that low-dose IL-2 could be a 
potential therapy to restore immune balance after HSCT. Another 
approach to manipulate Tregs in vivo was reported by Furusawa 
and colleagues (89). Clostridial products, like short chain fatty 
acids (SCFA) or mainly butyrate, can induce the differentiation 
of colonic Tregs in vitro and in vivo in mouse models (89). This 
points toward the necessity of host–microbiome interaction to 
establish immunological tolerance and homeostasis in the gut. 
Moreover, Mathewson and colleagues reported that restoring 
clostridial metabolites or the strain itself modulated intestinal 
epithelial cell integrity and mitigated GvHD in mice (63). Taken 
together, these findings strongly suggest that the right balance 
of gut microbiome may be crucial to induce Tregs for intestinal 
tolerance.
CD4+ and CD8+ T Cell Reconstitution
Memory T cells [central memory (TCM) and effector memory 
(TEM)], tissue resident memory cells (TRM), and effector cells (TEFF) 
cells are essential to control viral reactivations after allogeneic 
HSCT. Upon encountering antigens, memory cells differentiate 
to TEFF and lyse the infected cells and secret proinflammatory 
cytokines [e.g., IFN-γ and tumor necrosis factor-α (TNF-α)] 
(90). Immune surveillance of TCM occurs trafficking through sec-
ondary lymphoid organs, TEM and TEFF, through non-lymphoid 
organs (91). In contrary, TRM cells reside at various sites (e.g., liver, 
lungs, gut, and skin) and provide immediate antiviral response 
(cytotoxicity and secretion of IFN-γ) without trafficking (92). 
The reconstitution of CD4+CD45RA+ naive T cells, providing 
the broad range of TCR repertoire needed to control infections 
and to avoid the reappearance of leukemic cells, is essential after 
allogeneic HSCT (11, 93). The conditioning regimens applied, 
increasing patient age and occurrence of acute and chronic 
GvHD, have devastating effects on thymic function after HSCT 
(28, 93–95). Reconstitution of CD4+CD45RA+ naive T cells can 
be demonstrated by measuring TRECs. Immune reconstitution 
of CD4+ and CD8+ T cells is also essential for maintaining a GvL 
effect (1). Reconstitution of CD8+ T cells is faster than that of 
CD4+ T cells, which usually occurs around day +100 or later and 
is indicated by the inversion of the CD4+/CD8+ T cell ratio (1) 
early after HSCT (Table 1). The time period until complete recon-
stitution of CD4+ T cells can take up to 2 years after allogenic 
HSCT (96).
Major Factors Influencing T Cell Immune 
Reconstitution: GvHD and Immunosuppressive 
Treatment
Acute GvHD is one of the severe complications occurring early 
after HSCT contributing substantially to non-relapse mortality 
(NRM). Development of acute GvHD is influenced by human 
leukocyte antigen (HLA) disparities or gender mismatches 
between donor and recipient, the intensity of the conditioning 
regimen applied, CMV reactivation, and the stem cell source 
(97, 98). Acute GvHD can also occur in the HLA-identical 
transplant setting (siblings or matched unrelated donors) 
due to minor histocompatibility antigen differences between 
donor and recipient (98). Acute GvHD is an immune response 
directed against the host immune system, tissues, and organs 
(99, 100). GvHD by itself can inhibit T cell functions by limiting 
TCR diversity, T cell development, and dysfunction in cytokine 
production, most likely through damage of the BM and/or thy-
mus, apoptosis, and release of cytokines in a so-called “cytokine 
storm” (101).
Bone marrow gives rise to all hematopoietic lineages and 
is the homing site for memory cells of the adaptive immunity 
(102). Recently, BM has been established as an additional target 
of alloreactivity observed during GvHD leading to the deple-
tion of both hematopoietic progenitors and niche-forming cells 
(103), resulting in disrupted hematopoiesis and delayed immune 
reconstitution (104). Along with the BM, the thymus plays an 
important role in the maturation of hematopoietic precursors 
and T cell development (93). Acute GvHD substantially decreases 
TABLe 2 | Stem cell source influences immune reconstitution and 
complications after HSCT.
Complication PBSCs BM CB
aGvHD  ++ + +/−
Infections + + ++
Viral reactivations ++ ++ +/−
Relapse +/− ++ ++
The table summarizes the influence of different stem cell sources on the immune 
reconstitution and selected complications after HSCT. The degree of association is 
indicated by plus (+).
aGvHD, acute graft-versus-host disease; PBSCs, peripheral blood stem cells; BM, 
bone marrow; CB, cord blood; ++, high; +, moderate; and +/−, low.
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thymic output and thus recovery of CD4+ T cells and diversified 
T cell repertoires (93). Acute GvHD leads to a further skewing 
of the TCR repertoires of both CD4+ and CD8+ T cells as well as 
antigen-specific T cells (99). Both T lymphopenia and inadequate 
repertoire of CD4+ and CD8+ T cells for at least 1 year after trans-
plant foster recurrent infections with latent viruses.
In addition, treatment of patients with acute GvHD with 
corticosteroids or other immunosuppressive drugs increases the 
risk of viral reactivations (98, 105). It has been reported that the 
risk of CMV infections is directly related to the dose and duration 
of steroid administration (106). Administration of high doses of 
steroids was shown to be an independent risk factor for impaired 
functional recovery of CMV-specific CD4+ and CD8+ T cells 
(106). Moreover, Özdemir and colleagues reported that steroids 
induced a significant impairment of CD8+ T cells for producing 
TNF-α (107).
T Cell Depletion of the Stem Cell Graft
Although T cell depletion (TCD) of the stem cell graft reduces 
GvHD, it is associated with delayed immune reconstitution, 
infectious complications, and an increased risk of relapse (108). 
Thus, ex vivo T-cell depletion by either CD34+ cell selection or 
CD3+/CD19+ cell depletion has not been routinely performed 
and repletion protocols have been widely studied [e.g., HSV-Tk-
transduced T cell transfer, other donor lymphocyte infusion-based 
protocols (109, 110)]. In vivo T cell reducing or impairing agents 
include ATG [e.g., ATG-Fresenius; Germany, or thymoglobulin 
(thymo); Genzyme; USA] or anti-CD52 antibody (alemtuzumab 
or campath), a particularly powerful reagent for immunosuppres-
sion (108, 111). ATG administration leads to prolonged immuno-
suppression of both CD4+ T cells and CD4+CD25+CD127− Treg 
cells (111) and appears to have less severe effect on immune 
reconstitution when compared to campath (112).
Stem Cell Source
The source of stem cells can impact on both complications as 
well as time to immune reconstitution after allogeneic HSCT 
(Table  2). Investigators reported that the source of stem cells 
is a predictive factor for recovery of CMV-specific cytotoxic 
T  lymphocytes (CTL) (10). Recipients of PBSCs had improved 
functional CMV–CTL recovery and earlier CMV-specific CD4+ 
T cell reconstitution than patients given BM grafts (106, 113). 
These findings can be explained by the fact that PBSC grafts 
compared to BM contain more lymphocytes and higher numbers 
of CD4+CD45RO+ memory T cells (114).
influence of CD4+ and CD8+ T Cells 
on GvL
Graft-versus-leukemia is defined as an immune response directed 
against leukemia/tumor cells of the recipient after allogeneic 
HSCT. Over the years, several studies have shown that CD4+ and 
CD8+ T cells play an important role in establishing a GvL effect 
through various mechanisms such as cytotoxic T cells releas-
ing granzyme B and apoptosis mediated by FAS ligands (115). 
GvL is often associated with GvHD, but GvL responses against, 
e.g., minor histocompatibility antigens solely expressed on 
hematopoietic cells (mHA1) may be specifically directed against 
leukemic cells or the recipients’ hematopoietic cells. The precise 
role of CD4+ and CD8+ T cells for achievement of a GvL effect is 
not clearly understood today (115, 116). Complete depletion of 
T cells by CD34+ cell selection leads to a high incidence of relapse, 
resulting in death in about 20–50% of patients (117). T cell reple-
tion or donor lymphocyte infusions (DLI) can prevent relapse, 
but can lead to a higher probability of acute and chronic GvHD 
(118, 119). Several protocols tried to circumvent the problem 
of increased acute and chronic GvHD by delayed add-back of 
genetically modified T cells (109) or other manipulations of the 
donor’s lymphocytes such as selection of either CD4+ or CD8+ 
T cells prior to transfusion (120, 121).
virus-Specific immune Reconstitution 
(Antigen-Specific Cytotoxic T Cells) 
after HSCT
T cells are the most important effector cells in the control of viral 
infections. Thus, T cell reconstitution after allogeneic HSCT 
has a significant impact on the control of infectious complica-
tions. The first phase of virus-specific T cell reconstitution and 
expansion early after HSCT depends on the transfer of mature 
(effector, memory, or naive) virus-specific T cells within the 
donor graft and the resident antigen-specific cells (10, 122). 
Viral infections occur mostly between engraftment and day +90 
posttransplant (123). However, also late (after day +90) and 
recurrent CMV reactivations have been observed, which have 
been associated with impaired reconstitution or function of 
antiviral immunity (106). CMV is a latent virus, which belongs 
to the family of herpesviruses and is one among the common 
viral pathogens that can reactivate after HSCT. It reactivates in 
about 60–70% of CMV-seropositive patients, and the primary 
infection affects 20–30% of CMV seronegative recipients trans-
planted from CMV-seropositive donors (124). Uncontrolled 
CMV reactivations can lead to a life-threatening, multi-organ 
CMV disease such as retinitis, gastroenteritis, or pneumonia 
(125–127). Advances in CMV monitoring, preemptive antiviral 
therapy, and quantification of CMV–CTLs are crucial in the 
prevention of CMV disease (128). The most important risk fac-
tors for CMV infection include recipient CMV-seropositivity, 
TCD of the graft, and acute GvHD (123). Early reconstitution 
of antiviral immunity remains an essential issue for the control 
FiGURe 4 | Recovery of CMv-specific cytotoxic T lymphocytes after HSCT. Examples of reconstitution of CMV-specific cytotoxic T lymphocytes (CTLs) 
after HSCT for CMV-seropositive recipients transplanted from CMV-seropositive donors (R+/D+) (A) and CMV-seropositive recipients transplanted from CMV-
seronegative donors (R+D−) (B) are shown. CMV–CTL numbers per microliter of whole blood (left y-axis) were plotted against the time after HSCT (days). The right 
y-axis shows the number of pp65-positive cells/400,000 leukocytes (detection of CMV-reactivation). The CMV R+D+ patient had a CMV-reactivation by day +39 
and responded by an expansion of CMV–CTLs. No significant reconstitution of CMV–CTLs within the CMV R+D− patient was detected until day +100 despite the 
early CMV reactivation. Adapted from Ref. (136).
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of CMV reactivations after HSCT. The recovery of both CD8+ 
and CD4+ CMV-specific T cells may be a marker for protection 
against CMV reactivations (129).
Epstein–Barr virus infection is also a frequent viral complica-
tion after allogeneic HSCT, which may progress to EBV-associated 
posttransplant lymphoproliferative disease (PTLD) that causes 
unspecific symptoms such as fever and lymphadenopathy with a 
high viral load in the PB (130). These complications are mediated 
by several risk factors including TCD combined with reduced 
intensity conditioning (RIC) leading to impaired anti-EBV 
T cell-mediated immunity and persistence of residual recipient 
B cells (131). In addition, HLA disparity and acute GvHD have 
also been known to increase the risk of PTLD due to the delayed 
or impaired specific immune reconstitution (132).
However, other viral pathogens such as adenovirus (ADV), 
human herpes virus 6 (HHV6), BK-polyoma virus (BKV), and 
respiratory viruses occur less frequently in adult patients in 
comparison to CMV and EBV after allogeneic HSCT (133). The 
control of these viruses again depends upon the reconstitution of 
antiviral immunity.
Antigen-Specific T Cell Reconstitution 
and immunity Against CMv
Among the viruses mentioned above, T cell immune reconstitu-
tion against CMV has been studied most intensively and will 
be described in more detail below, as an example for virus (or 
any antigen)-specific T cell reconstitution and expansion. Apart 
from the above mentioned factors influencing T cell reconstitu-
tion (TCD of the graft; stem cell source, occurrence of acute or 
chronic GvHD), CMV serostatus of patient and donor is one of 
the most important variables influencing CMV-specific T cell 
immune reconstitution. CMV-seropositive recipients and donors 
(R+D+) have much faster reconstitution of CMV–CTLs (prior 
to day +50) and a subclinical CMV reactivation can even boost 
this development (106). On the other hand, CMV-seropositive 
recipients transplanted from CMV-seronegative donors (R+D−) 
lack the protective donor-derived immunity and hence have 
delayed recovery of antiviral immunity (between days +120 
and +150) and a higher risk for recurrent CMV reactivations 
(134). In Figure 4, examples of patients with typical CMV–CTL 
immune reconstitution for R+D+ and R+D− groups are shown 
to demonstrate the impact of CMV serostatus on CMV–CTL 
immune reconstitution. Additionally, it has been shown, that 
CMV–CTLs of recipient origin can survive the conditioning 
regimen and can add to the protection against CMV, especially 
in R+D− patients (135).
Does the Quantity or Quality of CMV-Specific  
T Cells Matter?
Recent technological developments in cellular immunology have 
aided in the understanding of antigen-specific T cell responses 
and the antiviral immunity after HSCT. With the instiga-
tion of multimer (e.g., tetramer and streptamer) technology, 
antigen-specific T cells are readily detected and isolated without 
stimulation (137–139). In order to study those cell functions, 
we can choose from a broad variety of assays including cytokine 
secretion assays, ELISPOT, intracellular staining, which require 
stimulation of cells with viral lysates, viral proteins, or peptides 
(137). As for CMV, immunity toward CMV immunodominant 
epitopes, which include pp65 and IE-1 antigens have been most 
intensively studied (140, 141).
Initiation of multimer technology allowed the investigation of 
CMV–CTLs in patients after allogeneic HSCT in order to search 
for a protective threshold (113, 137, 142). A chronological over-
view of selected publications on monitoring of CMV-specific T 
cell responses after HSCT, with the focus on the protective num-
bers of CMV–CTLs is provided in Table 3. It has been shown 
that the inability to control CMV reactivation following HSCT 
TABLe 3 | Selected publications on monitoring of CMv-specific T cell responses after HSCT.
Reference Key information
Altman et al. (146) First use of MHC tetramers to enumerate and characterize antigen-specific T cells
Cwynarski et al. (113) Protection from CMV reactivation with ≥10 CMV–CTL cells/μL blood
Gratama et al. (142)  (1) Failure to recover HLA-A*02-NLV–CMV–CTLs is associated with the development of CMV disease
 (2) Number of HLA-A*02-NLV–CMV–CTLs in the grafts administered to CMV-seropositive HSCT recipients is inversely correlated with the 
number of recurrent CMV infections
Aubert et al. (147) Less than 20 cells/μL of HLA-A*02 CMV–CTLs predicted episodes of viral replication
Chen et al. (148) More than 10–20 cells/μL CMV–CTLs conferred protection against CMV reactivation
Özdemir et al. (107) Inability to control CMV reactivation is caused by impaired function of CMV–CTLs rather than an inability to recover sufficient numbers of 
CMV-specific T cells
Lacey et al. (149) CMV-specific cellular immune responses restricted by HLA-B*07 dominated those restricted by HLA-A*02
Akiyama et al. (150) Frequency of HLA-A*24 CMVpp65 tetramer-positive staining correlated with cytotoxicity and IFN-γ production
Bunde et al. (151) High frequencies of IFN-γ producing IE-1, but not pp65-specific CD8+ T cells, correlated with protection from CMV disease
Lilleri et al. (152) Levels of CD4+ T cells below 1 cell/μL and of CD8+ T cells less than 3 cells/μL did not protect against recurrent CMV infection
Gratama et al. (153)  (1) CMV–CTLs provided protection against recurrent CMV reactivations
 (2) CMV disease appeared to be prevented by the IE-1-specific subset rather than the pp65-specific CD8+ T cell subset
Koehl et al. (154)  (1) Numbers of CMV–CTLs differ significantly depending on the HLA type
 (2) Number of CMV–CTLs below 10 cells/μL does not correlate with susceptibility for CMV reactivation
Giest et al. (155) HLA-A*24/pp65- and HLA-B*35/pp65-CTLs correlated with protection from CMV reactivation at significantly lower cell levels than 
HLA-A*01/pp50- and HLA-A*02/pp65-CTLs
Gratama, et al. (156) Less than 7 cells/μL of CMV–CTLs during the first 65 days after transplantation was a significant risk factor for CMV-related complications
Borchers et al. (134)  (1) Presence of CMV–CTLs before day +50 and their expansion after reactivation protected against recurrent CMV reactivations
 (2) CMV–CTL reconstitution was delayed in the CMV R+D− group
Lilleri et al. (157) Combination of CMV–CTL monitoring and viral monitoring can be used to direct preemptive treatment with antiviral drugs
Borchers et al. (136)  (1) 1 cell/μL of CMV–CTLs between days +50 and +75 marked the beginning of immune response against CMV in the CMV R+D+ group
 (2) Expansion of CMV
 (3) Sequential monitoring of CMV
Reused from Ref. (137) by permission from Elsevier, License Number 3922460449459.
MHC, major histocompatibility complex; CMV–CTL, cytomegalovirus cytotoxic T lymphocytes; HLA, human leukocyte antigen; IFNγ, interferon gamma; IE-1, immediate early-1.
10
Ogonek et al. Immune Reconstitution Post-HSCT
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 507
is due to the impaired function of antigen-specific CD8+ T cells 
rather than an inability to recover sufficient numbers of CMV-
specific T cells (143). Although CMV–CD8+ CTLs have been 
considered as the main antiviral effector cells, CMV-specific 
CD4+ T cells have been shown to play a crucial role in expan-
sion and activation of CMV–CTLs, maintaining a long-term and 
efficient immunity against CMV (129). It has been reported that 
CD4+ and CD8+ CMV-specific T cells follow similar patterns 
of reconstitution (144), and their functional reconstitution 
is correlated with the absolute CD4+ or CD8+ T cell numbers 
(106, 145). So far, there is no threshold for protective levels 
of CMV-specific T cells applicable for all patients. Sequential 
monitoring of individual patients for the kinetics of CMV–CTL 
recovers, their ability to produce cytokines and expansion upon 
reactivation, are currently being used to detect recurrent CMV 
reactivations (136) (Figure 4). In summary, both the quantity 
and quality of immune reconstitution are important for prevent-
ing viral infection after allogeneic HSCT.
CONCLUSiON AND FUTURe OUTLOOK
Reconstitution of the donor-derived immune system is essential 
for control of infectious complications, modulation of GvHD, 
and relapse control, thus contributing to long-term survival. 
In this review, we have described the major events in immune cell 
reconstitution, considering the most important cell types, their 
approximate time of reconstitution, and their interaction after 
HSCT. The recovery of the innate immunity is vital, especially 
in the absence of CD4+CD45RO+ memory and CD4+CD45RA+ 
naive T cells.
Today, the understanding of CD4+CD25+CD127− regula-
tory T cells has advanced significantly in both preclinical 
and clinical models for GvHD. The remaining challenge is 
to generate large amounts of CD4+CD25+CD127− Tregs with 
high purity and stable Foxp3-expression in a cost effective 
way. A further clinical problem is the optimal time point of 
Treg application. If Tregs are administered to treat patients 
with steroid-refractory GvHD, there may be a substantial 
delay between production and application and, thus, lack of 
feasibility and treatment success. Furthermore, the impact of 
ongoing systemic immunosuppression on Treg cell function 
has to be considered in clinical trials. A further aspect to be 
solved in the future is to optimize tissue conditions for survival 
and expansion of T regs, as these cells are under the strong 
control of local microbiota especially in the main target tissues 
of GvHD.
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